Biogen’s R&D strategy fails to impress after Alzheimer’s trial flopThe dust has settled at Biogen following the company’s disastrous announcement that it was ending development of Alzheimer’s Share XBiogen’s R&D strategy fails to impress after Alzheimer’s trial flophttps://pharmaphorum.com/news/biogens-rd-strategy-fails-to-impress-after-alzheimers-trial-flop/
European regulator restricts use of Sanofi MS drug LemtradaThe European drug regulator has called for a review of Sanofi’s multiple sclerosis drug Lemtrada following reports of Share XEuropean regulator restricts use of Sanofi MS drug Lemtradahttps://pharmaphorum.com/news/european-regulator-restricts-use-of-sanofi-ms-drug-lemtrada/
Merck’s oral MS drug finally gets FDA okayMerck KGaA has finally claimed an FDA approval for its oral multiple sclerosis therapy Mavenclad, eight years after Share XMerck’s oral MS drug finally gets FDA okayhttps://pharmaphorum.com/news/mercks-oral-ms-drug-finally-gets-fda-okay/
MS drug market heats up as FDA backs Novartis’ new pillThe FDA has approved Novartis’ Mayzent (siponimod) multiple sclerosis pill for relapsing forms of the disease, dealing a Share XMS drug market heats up as FDA backs Novartis’ new pillhttps://pharmaphorum.com/news/ms-drug-market-heats-up-as-fda-backs-novartis-new-pill/
Celgene refiles potential MS blockbuster ozanimod with FDACelgene has filed its highly anticipated oral MS drug ozanimod with the US regulator, more than a year Share XCelgene refiles potential MS blockbuster ozanimod with FDAhttps://pharmaphorum.com/news/celgene-refiles-potential-ms-blockbuster-ozanimod-with-fda/
Merck KGaA admits to ‘challenging’ 2018, as currencies hit salesGermany’s Merck KGaA has described 2018 as a “challenging” year, which saw profits hit by currency headwinds and Share XMerck KGaA admits to ‘challenging’ 2018, as currencies hit saleshttps://pharmaphorum.com/news/merck-kgaa-admits-to-challenging-2018-as-currencies-hit-sales/
Novartis and Oxford University begin R&D tie-upNovartis and Oxford University have begun a partnership that will attempt to use artificial intelligence to predict how Share XNovartis and Oxford University begin R&D tie-uphttps://pharmaphorum.com/news/novartis-and-oxford-university-begin-rd-tie-up/
Alkermes/Biogen hope for less tummy trouble with new MS pillAlkermes and Biogen have filed a new multiple sclerosis pill with the FDA, which they hope will treat Share XAlkermes/Biogen hope for less tummy trouble with new MS pillhttps://pharmaphorum.com/news/alkermes-biogen-hope-for-less-tummy-trouble-with-new-ms-pill/
Roche beats revenue forecasts as sales of old drugs take off in ChinaRoche has beaten analysts’ revenue forecasts in the third quarter, after mounting sales of its older drugs in Share XRoche beats revenue forecasts as sales of old drugs take off in Chinahttps://pharmaphorum.com/news/roche-beats-revenue-forecasts-as-sales-of-old-drugs-take-off-in-china/
